Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Form 8.5 (EPT/NON-RI)

13 Sep 2010 13:45

RNS Number : 5814S
Nomura Code Securities Limited
13 September 2010
 



FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Nomura Code Securities Ltd

(b) Name of offeree in relation to whose relevant securities this form relates:

Silence Therapeutics Ltd

(c) Name of the party to the offer with which exempt principal trader is connected:

Silence Therapeutics Ltd

(d) Date dealing undertaken:

10 Sep 2010

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

 

NO

 

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.0

563,377

0.2

(2) Derivatives (other than options):

0

(3) Options and agreements to purchase/sell:

0

 

TOTAL:

0

0.0

563,377

0.2

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

None

Details, including nature of the rights concerned and relevant percentages:

None

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ord shares

Purchase

35,000

11.5 p

Total

Purchases:

35,000

Ord shares

Sale

428,449

11.67 p

Total

Sales:

428,449

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

No

 

 

Date of disclosure:

13 Sep 2010

Contact name:

Niall Campbell

Telephone number:

020 7776 1226

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEOUOSURRSAKAAR
Date   Source Headline
28th Apr 20107:00 amPRNSilence (AIM: SLN) to Release Prelim Results on April 29
21st Apr 20107:00 amPRNSilence (AIM:SLN), AstraZeneca Extend RNAi Collaboration
15th Apr 20107:00 amPRNSilence Therapeutics (AIM: SLN) Appoints New CFO
13th Apr 20107:00 amPRNSilence(AIM:SLN) Integrates Assets from Intradigm Merger
30th Mar 20107:02 amPRNResearch Update
19th Mar 20103:27 pmPRNHolding(s) in Company
1st Mar 20107:00 amPRNDirectorate Change
15th Feb 20107:00 amPRNDirector/PDMR Shareholding
12th Feb 20103:28 pmPRNSenior Independent Director
12th Feb 20101:28 pmPRNNotification of Results
28th Jan 20103:00 pmPRNTotal Voting Rights
8th Jan 20101:00 pmPRNHolding(s) in Company
5th Jan 20101:35 pmPRNAcquisition and Issue of Equity
4th Jan 201012:40 pmPRNEGM Statement
17th Dec 200912:05 pmPRNStatement re Posting of Document
16th Dec 20095:03 pmRNSSchedule 1 - Silence Therapeutics plc
16th Dec 200912:00 pmRNSRestoration - Silence Therapeutics plc
16th Dec 200912:00 pmPRNAcquisition
14th Dec 200912:45 pmPRNAGM Statement
20th Nov 20097:00 amPRNNotice of AGM
15th Oct 20097:05 amPRNPatent Update
2nd Oct 20094:55 pmPRNCorrection : Half-yearly Report
30th Sep 20097:00 amPRNHalf-yearly Report
29th Sep 200910:15 amPRNTemporary Suspension
29th Sep 200910:15 amRNSSuspension - Silence Therapeutics plc
17th Sep 20097:00 amPRNNotice of Results
1st Sep 20094:40 pmRNSSecond Price Monitoring Extn
1st Sep 20094:35 pmRNSPrice Monitoring Extension
28th Aug 20094:25 pmPRNHolding(s) in Company
27th Aug 20094:40 pmRNSSecond Price Monitoring Extn
27th Aug 20094:35 pmRNSPrice Monitoring Extension
27th Aug 20097:00 amPRNRe Agreement
26th Aug 200911:30 amPRNHolding(s) in Company
14th Jul 200911:30 amPRNIssue of Equity
1st Jul 20094:40 pmRNSSecond Price Monitoring Extn
1st Jul 20094:35 pmRNSPrice Monitoring Extension
24th Jun 20097:00 amPRNAnnual Financial Report
23rd Jun 20097:00 amPRNResearch Update
19th Jun 20094:35 pmRNSPrice Monitoring Extension
3rd Jun 200912:05 pmPRNStatement re Approval for Clinical Trial
22nd May 20094:40 pmRNSSecond Price Monitoring Extn
22nd May 20094:35 pmRNSPrice Monitoring Extension
12th May 20094:40 pmRNSSecond Price Monitoring Extn
12th May 20094:35 pmRNSPrice Monitoring Extension
11th May 20094:40 pmRNSSecond Price Monitoring Extn
11th May 20094:35 pmRNSPrice Monitoring Extension
7th May 20094:40 pmRNSSecond Price Monitoring Extn
7th May 20094:35 pmRNSPrice Monitoring Extension
5th May 20094:51 pmRNSSecond Price Monitoring Extn
5th May 20094:46 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.